Modified titration intratympanic gentamicin injection for unilateral intractable Ménière’s disease

Abstract

This study looked into the efficacy of a modified titration protocol of intratympanic gentamicin injection (ITG) in the patients with unilateral intractable Ménière’s disease (MD). Modified titration protocol of ITG at a low dose (20 mg/mL) was administered to 10 patients with definite unilateral intractable MD. After initial first two fixed ITGs on weekly basis, the patients might or might not be given any more injections, depending on the appearance of unilateral vestibular loss (UVL). ITG was terminated if the patients satisfied the criteria of UVL. All patients were followed-up for at least two years. The effects of ITG on the vertigo attack, functional level scores and postural balance were evaluated. Of the 10 cases, 8 showed the sign of UVL after receiving initial two ITGs and were not given any more intratympanic injections, and the other 2 patients were administered three ITGs. A two-year follow-up revealed that complete and substantial vertigo control was achieved in 9 cases, and limited vertigo control in 1 patient. Hearing level was lowered in 2 patients. The posture stability and functional level scores were improved. Our study showed that the modified titration protocol of ITG at a low dose could effectively control vertigo in patients with unilateral intractable MD.

Keywords

Ménière’s disease / inner ear / injection / gentamicin

References

[1] SajjadiH, PaparellaMM. Meniere’s disease. Lancet, 2008, 372(9636): 406-414 PMID: 18675691

[2] PerezN, MartinE, Garcia-TapiaR. Intratympanic gentamicin for intractable Meniere’s disease. Laryngoscope, 2003, 113(3): 456-464 PMID: 12616197

[3] MartinE, PerezN. Hearing loss after intratympanic gentamicin therapy for unilateral Meniere’s Disease. Otol Neurotol, 2003, 24(5): 800-806 PMID: 14501459

[4] FowlerE ffixJr. Streptomycin treatment of vertigo. Trans Am Acad Ophthalmol Otolaryngol, 1948, 52: 293-301 PMID: 18915191

[5] SchuknechtHF. Ablation therapy in the management of Meniere’s disease. Acta Otolaryngol Suppl, 1957, 132: 1-42 PMID: 13457879

[6] LangeG, MaurerJ, MannW. Long-term results after interval therapy with intratympanic gentamicin for Meniere’s disease. Laryngoscope, 2004, 114(1): 102-105 PMID: 14710003

[7] MinorLB. Intratympanic gentamicin for control of vertigo in Meniere’s disease: vestibular signs that specify completion of therapy. Am J Otol, 1999, 20(2): 209-219 PMID: 10100525

[8] MinorLB, SchesselDA, CareyJP. Meniere’s disease. Curr Opin Neurol, 2004, 17(1): 9-16 PMID: 15090872

[9] BodmerD, MorongS, StewartC, et al. . Long-term vertigo control in patients after intratympanic gentamicin instillation for Meniere’s disease. Otol Neurotol, 2007, 28(8): 1140-1144 PMID: 18084826

[10] WassonJ, UpileN, PfleidererA. Intratympanic gentamicin treatment for unilateral Meniere’s disease: long-term follow up of a proven regime. J Laryngol Otol, 2013, 127(1): 20-24 PMID: 23217984

[11] AtlasJT, ParnesLS. Intratympanic gentamicin titration therapy for intractable Meniere’s disease. Am J Otol, 1999, 20(3): 357-363 PMID: 10337978

[12] KatzenellU, GordonM, PageM. Intratympanic gentamicin injections for the treatment of Meniere’s disease. Otolaryngol Head Neck Surg, 2010, 143(3): S24-S29 PMID: 20970688

[13] DaneshiA, JahandidehH, PoustiSB, et al. . One-shot, low-dosage intratympanic gentamicin for Meniere’s disease: Clinical, posturographic and vestibular test findings. Iran J Neurol, 2014, 13(1): 33-39 PMCID: 3968355 PMID: 24800045

[14] Committee on HearingEquilibrium guidelines for the diagnosisevaluation of therapy in Menière's disease.. American Academy of Otolaryngology-Head and Neck Foundation, Inc.. Otolaryngol Head Neck Surg, 1995, 113(3): 181-185

[15] LiuB, ZhangS, LengY, et al. . Intratympanic injection in delayed endolymphatic hydrops. Acta Otolaryngol, 2015, 135(10): 1016-1021 PMID: 26050741

[16] ChungWH, ChungKW, KimJH, et al. . Effects of a single intratympanic gentamicin injection on Meniere’s disease. Acta Otolaryngol Suppl, 200761-66

[17] QuaglieriS, GattiO, RebecchiE, et al. . Intratympanic gentamicin treatment ‘as needed’ for Meniere’s disease. Long-term analysis using the Kaplan-Meier method. Eur Arch Otorhinolaryngol, 2014, 271(6): 1443-1449 PMID: 23778723

[18] De BeerL, StokroosR, KingmaH. Intratympanic gentamicin therapy for intractable Meniere’s disease. Acta Otolaryngol, 2007, 127(6): 605-6012 PMID: 17503229

[19] CasaniAP, CerchiaiN, NavariE, et al. . Intratympanic gentamicin for Meniere’s disease: short- and long-term follow-up of two regimens of treatment. Otolaryngol Head Neck Surg, 2014, 150(5): 847-852 PMID: 24477826

[20] HuonLK, FangTY, WangPC. Outcomes of intratympanic gentamicin injection to treat Meniere’s disease. Otol Neurotol, 2012, 33(5): 706-714 PMID: 22699980

[21] WuIC, MinorLB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Meniere’s disease. Laryngoscope, 2003, 113(5): 815-820 PMID: 12792316

[22] HarnerSG, DriscollCL, FacerGW, et al. . Long-term follow-up of transtympanic gentamicin for Meniere’s syndrome. Otol Neurotol, 2001, 22(2): 210-214 PMID: 11300271